COUNTERSTRIKE – Counteracting sarcopenia with proteins and exercise

Project period: 2015 – 2019

The main aim of COUNTERSTRIKE is to develop a tool for rapidly assessing age-related loss of skeletal muscle mass, termed sarcopenia, to find individual treatments to promote the maintenance of a healthy level of skeletal muscle mass.

The University of Copenhagen is running an ambitious intervention study Counteracting Age-related Loss of Skeletal Muscle Mass (CALM) aimed at providing evidence-based recommendations for alleviating sarcopenia through protein supplementation and exercise.

The project is collecting a large number of blood and faecal samples to determine the impact of increased protein intake and exercise on the gut microbiota and the blood metabolome.

COUNTERSTRIKE aims to complement the CALM project with a full metabolomics investigation of all samples in the CALM cohort with an emphasis on determining the lipoprotein particle distribution and linking this to gut microbiota, metabolomic potential and host physiological parameters focusing on skeletal muscle mass.

Global screening and individual counterstrike

The lipoprotein particle distribution predicts cardiovascular outcomes and is associated with obesity and insulin resistance. Body weight decreases with age, whereas a more atherogenic lipid profile is common, but little is known about the lipoprotein particle distribution in elderly people or the effect of exercise.

It is the ambition of this consortium, including national and international, academic and industrial partners, to establish a rapid screening method to determine the lipoprotein particle distribution based on nuclear magnetic resonance (NMR) spectroscopy, apply it to the CALM cohort and link the results to gut microbiota and host metabolism, making them available for future research.

A new spectroscopy-based screening method will enable the global screening of elderly people to determine each individual’s health status and allow for an individual “counterstrike” against sarcopenia.






Funded by:

Innovation Fund Denmark's logo

COUNTERSTRIKE has received DKK 15,633,418 from Innovation Fund Denmark

Additional funding from: Bruker BioSpin GmbH, Arla Foods Amba, Unilever R&D Vlaardingen, and all university partners

Project: Counteracting Sarcopenia with proteins and exercise - screening the CALM cohort for lipoprotein biomarkers - COUNTERSTRIKE
Period:  1 April 2015 - 31 March 2019

Picture of Counterstrike logo


Professor with special responsibilities Dennis Sandris NielsenAssociate Professor
Microbiology and Fermentation